News coverage about Horizon Therapeutics (NASDAQ:HPTX) has been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.7504312361807 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Horizon Therapeutics (NASDAQ:HPTX) traded up 0% during midday trading on Monday, reaching $46. The company has a 50 day moving average price of $46.00 and a 200 day moving average price of $46.00. Horizon Therapeutics has a 12 month low of $46.00 and a 12 month high of $46.00.
Horizon Therapeutics Company Profile
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.